GlassScriptPhysician profile
Thomas M Dawes
NPI 1386668473
$5,440.05
in general payments reported to CMS, 2019-2025
38 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $629 · 2021: $1,008 · 2022: $675 · 2023: $961 · 2024: $732 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.37 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $678.29 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $527.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.77 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $370.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $290.88 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $287.01 | 2019-2023 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $203.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.49 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $159.13 | 2019-2020 | |
| Boston Scientific Corporation | $133.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $131.73 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $118.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $117.26 | 2021-2024 | Nexletol |
| Allergan, INC. | $107.79 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.96 | 2019-2023 | Verquvo, Segluromet, Steglujan |
| Biotronik Nro, INC. | $88.04 | 2025 | Prospera |
| Mannkind Corporation | $80.06 | 2019 | |
| Aclaris Therapeutics, INC. | $75.59 | 2019 | |
| Baxter Healthcare | $63.91 | 2022 | |
| Bioventus LLC | $57.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.21 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.02 | 2019-2021 | |
| Grifols USA, LLC | $45.16 | 2023-2024 | Prolastin-C Liquid |
| Viiv Healthcare Company | $29.13 | 2021 | |
| Edwards Lifesciences Corporation | $25.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $24.87 | 2021 | |
| Seqirus USA INC | $22.57 | 2025 | Fluad, Flucelvax |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.96 | 2022 | |
| Eisai INC. | $20.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.87 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.50 | 2022 | |
| Astellas Pharma US INC | $15.59 | 2023 | Veozah |
| Alkermes, INC. | $15.34 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2024 | Sotyktu |
| Tms Neurohealth Centers INC. | $13.09 | 2025 | Tms Neurohealth Centers INC. |
| Medtronic USA, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dawes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.